載入...
Low dose balsalazide (1.5 g twice daily) and mesalazine (0.5 g three times daily) maintained remission of ulcerative colitis but high dose balsalazide (3.0 g twice daily) was superior in preventing relapses
BACKGROUND—Balsalazide is a new 5-aminosalicylic acid (5-ASA) containing prodrug. Its efficacy in comparison with standard mesalazine therapy and the optimum dose for maintaining remission of ulcerative colitis are still unclear. AIMS—To compare the relapse preventing effect and safety profile of tw...
Na minha lista:
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
2001
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC1728533/ https://ncbi.nlm.nih.gov/pubmed/11709512 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/gut.49.6.783 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|